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Abstract
T-cell activation and differentiation depend on the signal strength
received by the T-cell receptor and on signals provided by co-
stimulatory molecules. The most prominent co-stimulatory molecule
is CD28, which controls the activation of naïve and memory T cells
by antigen presented on professional antigen-presenting cells.
Blocking of the CD28-CD80/86 pathway has been an appealing
strategy for inducing tolerance in autoimmune diseases where the
disease-inducing autoantigens are not known. Although CD28 has
maintained its unique position, the past decade has witnessed the
recognition that a large number of regulatory molecules on T cells
must be stimulated to generate a fully protective immune response.
These regulatory receptors differ in their preferential expression on T-
cell subsets, in the ligands that they recognize, and in the signaling
pathways that they trigger. They have in common the fact that they
provide information on the cellular environment in which the T-cell
response occurs. By intercepting these signals, we may be able to
influence disease-relevant T-cell responses in autoimmune diseases
while potentially minimizing broad immunosuppression.
Introduction
Since its first introduction, the concept of co-stimulation has
sparked the interest of autoimmunity researchers and
immunologists interested in translational applications, because
it holds the promise to influence immune responses without
needing to define the antigen involved. The basic idea is that
co-stimulatory signals decide whether an activation signal
translates into an immune response or into tolerance. The
concept goes back to the report by Cohn and Bretscher [1],
who postulated in the 1970s that regulatory control of a
system requiring high sensitivity and high specificity, such as
the adaptive immune system, must rely on two independent
signals.
Lafferty [2] and Jenkins and Schwartz [3] introduced this
concept into T-cell immunology in the 1980s. Signal 1 is
delivered by the T-cell receptor (TCR) recognizing the
antigenic peptide within the context of the major histo-
compatibility complex (MHC) molecule. However, stimulation
of the TCR alone does not induce a productive T-cell
response, but renders the T cells anergic. A second signal,
generally provided by molecules expressed on the antigen-
presenting cell (APC), is required to optimize a T-cell
response. In this concept, the APC holds a central position
because of its ability to provide a co-stimulatory signal.
Dendritic cells (DCs) are of particular importance in T-cell
priming, but B cells and macrophages can also function as
APCs. Under normal conditions, other cell types, such as
epithelial or stromal cells, cannot induce an immune response
because they lack the co-stimulatory ligand. Subsequent
studies have shown that APCs need activation signals to
provide co-stimulatory ligands, for example through the
activation of Toll-like receptors [4,5].
The model has placed co-stimulation at the central decision
point in the induction of an immune response; in fact, stimula-
tion of a naïve T-cell response is unlikely in the absence of co-
stimulatory signals. It is therefore not surprising that this
decision point is thought to be an optimal target for immune
interventions.
The CD28-CD80/CD86 pathway is the classical co-
stimulatory pathway and can be considered to be unique
[6,7]. CD28 is constitutively expressed on naïve CD4+ and
CD8+ T cells. In contrast, CD80 and CD86 are inducible on
DCs and other APCs upon stimulation. The best way to
inhibit CD28-CD80/CD86 interaction is by means of
cytotoxic T-lymphocyte antigen (CTLA)4-immunoglobulin (Ig).
CTLA4 is a negative regulatory receptor that is expressed
after stimulation and functions to limit T-cell responses.
Because it binds to CD80 and CD86 with greater affinity
than to CD28, it can outcompete CD28. A CTLA4-Ig
construct with inserted mutations to inactivate the Fc element
has been introduced under the generic name abatacept and
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was recently approved for treatment of rheumatoid arthritis
(RA), clearly documenting the validity of this treatment
concept [8]. It has been less effective in transplantation
models, but recent data from a nonhuman primate model [9]
indicate that a mutated abatacept - namely belatacept, which
binds CD86 with greater affinity - has promising effects.
In essence, co-stimulation implies that naïve T-cell responses
are and should be context dependent. This concept has been
expanded in recent years in several dimensions. First, it is
now clear that T cells sense co-stimulatory as well as co-
inhibitory cues from their environment [10]. Co-inhibitory
signals are equally important to our understanding of immune
regulation; in fact, the information transmitted upon cell
activation constitutes an integration of positive and negative
signals. Negative regulatory receptors are not reviewed here,
and we refer the interested reader to recent excellent reviews
[10-12]; targeting these receptors will first find clinical
applications in vaccine responses or in tumor immunology,
and not in autoimmunity. The second development came from
the insight that co-stimulatory signals also function if they do
not coincide spatially or temporally with the TCR-mediated
recognition of MHC-peptide complexes. Many co-stimulatory
molecules are only induced subsequent to T-cell activation
and function in amplification and differentiation. Finally, it is
now being recognized that co-stimulatory control is not only a
concept for the early stages of an immune response, when
naïve T cells encounter antigen for the first time and must
make the decision between being tolerant or being driven into
proliferation. Context dependency of T-cell responses is
evident at all stages of the immune response. For naïve T
cells or central memory T cells, this context represents the
recognition of ligands on APCs (Figure 1); for effector cells,
regulatory signals from stromal cells gain in importance and
are of relevance for autoimmune diseases where T-cell
effector functions are exerted at immunoprivileged sites and
induce tissue damage.
CD28-mediated co-stimulation
The importance of CD28-mediated signals was first empha-
sized by the immunodeficiency observed in CD28-deficient
mice [13-17]. These mice have compromised responses to
an array of immune functions, including deficient germinal
center formation and immunoglobulin isotype class switching,
reduced delayed hypersensitivity responses, and reduced
helper cell differentiation. Also, CD8-dependent cytotoxic
responses are impaired, although not completely abrogated.
CD28 is expressed on all naïve T cells, but may be lost with
T-cell differentiation. This loss is frequently observed in
humans and in nonhuman primates, and in particular involves
the CD8+ effector cell population [18]. CD4+ T cells can also
be affected, in particular in patients with autoimmune
conditions. Loss of CD28 occurs normally with age, but this
process may be accelerated in susceptible individuals. One
contributing factor may be tumor necrosis factor (TNF), which
has been shown to downregulate the number of CD28
molecules that are expressed on each individual cell and
which may also in part be responsible for the complete loss
of CD28 expression in some cells [19]. It should be noted
that cell surface expression of CD28 in rodent models is
different, and that CD28 is expressed by all murine functional
T-cell subsets, irrespective of age or disease. Murine models
may therefore represent an imperfect model of CD28
function in humans, with its more restrictive expression
patterns on naïve and central memory CD4+ and CD8+ cells.
Figure 1
Co-stimulatory receptor-ligand pairs in the initiation of a T-cell response. CD27 and CD28 are co-stimulatory molecules that are constitutively
expressed. Their ligands CD70, CD80, and CD86 are inducible on dendritic cells upon their activation. The CD154-CD40 interaction represents
an important amplification loop that upregulates the expression of CD80 and CD86. MHC, major histocompatibility complex; TCR, T-cell receptor.Page 3 of 10
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CD28 is stimulated by its recognition of CD80 and CD86 on
APCs (Figure 1) [20,21]. Expression of both of these ligands
is not constitutive but activation induced. It is possible that
CD80 and CD86 have distinct functions, and that CD86 is
induced later in the immune response than is CD80.
Expression of both of these molecules is dependent on
various activation stimuli, such as Toll-like receptor ligands.
One important amplification loop is the stimulation of CD40
on DCs by CD40 ligand expressed on activated CD4 T cells,
which upregulates CD80/CD86 expression [22].
CD28 is a separate signaling unit, independent of the TCR
activation complex, which is very much in line with the two-
signal hypothesis. Initially, it was thought that each of these
two signaling pathways would be unique and only partially
overlapping, if at all, and that information and integration
would occur at the level of transcription. More recent studies,
however, have shown that this is not the case and that signal
integration occurs early [23]. CD28 does not stimulate all
signaling effectors that are activated by the TCR, but primarily
provides a potent synergistic signal for transcription factors
such as nuclear factor-κB (NF-κB), nuclear factor of activated
T cells (NFAT), and activator protein-1 (AP1) [24-26]. CD28
therefore functions mainly as an amplifying mechanism to
overcome signaling thresholds that, in principle, are
obtainable by ligation of the TCR alone. CD28 stimulation is
mandatorily required at low TCR occupancy, because it
occurs in most antigen-specific responses. However, it may
be partially or totally dispensable in responses to high-affinity
antigens with high TCR occupancy or in situations where the
TCR threshold is lower, as seen in effector cell populations.
In this model, the contribution of CD28 co-stimulation is more
qualitative than quantitative [27,28]. This concept has been
supported by gene expression studies comparing TCR-
induced gene expression in the presence or absence of co-
stimulation [26,29]. CD28 co-stimulation was unable to
induce transcription of any gene that could not be induced by
TCR stimulation alone. However, CD28 co-stimulation was
able to amplify or suppress many of the TCR-induced genes
to a varying degree. CD28-mediated signaling is not just
repetitive of TCR signaling, but sets a different emphasis that
shifts the balance of signal events and influences feedback
circuits. In this context it is important to note that anti-CD28
antibodies that bind to the laterally exposed C’’D loop of the
immunoglobulin-like domain of CD28 - distant from the
natural ligand-binding domain - induces NF-κB signaling by
itself without any need for TCR stimulation [30]. This stimu-
latory activity of some anti-CD28 antibodies led to the
dramatic complications in the Tegenero trial [31].
CD28 signals are mediated through phosphorylated tyrosines
that are not part of an ITAM (immunoreceptor tyrosine-based
activation motif) motif and by proline-rich motifs in its
cytoplasmic tail. CD28 signaling also does not involve the
LAT-SLP76 complex, which is the basic signaling module of
the TCR intracellular signaling complex. Instead, the CD28
signaling pathway primarily involves a small subset of
signaling molecules that are also implicated in TCR signal
transmission, in particular the phosphoinositide-3 kinase
(PI3-K) pathway with downstream activation of AKT [32,33],
and activation of TEC protein kinases and of interleukin-2-
inducible T-cell kinases [27,34]. AKT activation cooperates
with the TCR-induced activation of protein kinase C (PKC)θ
to activate the NF-κB pathway, which is otherwise only
slightly activated by TCR alone. Activation of TEC and
interleukin-2-inducible T-cell kinases are crucial for the
regulation of phospholipase C-γ1, contributing to intracellular
calcium signal as well as activation of PKC.
Although the main function of CD28 appears to lie in
lowering the TCR threshold to antigen-specific stimuli, it has
a selective imprint on the transcriptional program induced by
TCR-mediated activation rather than a random effect. In
addition to its activation of selected transcription factors such
as NF-κB, AP1, and NFAT, CD28 co-stimulation has a major
impact on DNA demethylation and chromatin remodeling.
Most of the biological processes that are influenced by CD28
co-stimulation pertain to T-cell clonal expansion and
differentiation. Typical examples are that CD28 co-stimulation
induces an anti-apoptotic program, accelerates cell cycle
progression, and upregulates metabolic pathways [32,35,36].
This pro-proliferative activity makes sense if one considers
that the major functions of CD28 co-stimulation are to allow
naïve T cells to be activated and clonally expanded.
How does this appreciation of CD28-mediated co-stimulation
help us to understand the action of CTLA4-Ig treatment in
RA? Although CD28-mediated co-stimulation functions in
central memory T-cell activation and can directly or indirectly
modulate CD8+ memory T-cell responses in murine systems,
CTLA4-Ig blockade should affect naïve T-cell responses
more than effector T cells [37,38]. This has implications for
the safety and the side effects predicted to occur with
CTLA4-Ig treatment. Immune responses to novel antigens
could be importantly abrogated, as is the case in a primary
exposure to infectious viruses such as new influenza strains.
Indeed, a single dose of CTLA4-Ig in young healthy adults
reduced vaccine responses to a peptide antigen, although it
could not completely abrogate them [39]. The risk from
disabling T cells with CTLA4-Ig in nonimmune patients is not
known at present, but it is possible that host defenses are
deficient. T-cell responses for which a memory T-cell
response has already been established may be less affected,
and patients may only be at moderate risk for reactivation of
chronic viral infections such as herpes zoster or viral hepatitis.
In the clinical studies conducted thus far, the incidence of
herpes zoster reactivation has been estimated at 0.7%, which
corresponds to the incidence rate in a normal population of
65-year-old individuals [40].
How then is CTLA4-Ig efficacious in RA, if it preferentially
targets naïve and memory T cells? Effector T-cell populations
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particular because they have frequently lost CD28 expres-
sion, which is in sharp contrast to rodent systems. It is
possible that CD28 blockade works upstream of these
effector cells and that the disease activity in RA is dependent
on the continuous recruitment of naïve and central memory
cells into the effector cell pool. In this model, continuous
disease activity may be dependent on progressive epitope
spreading and broadening of the autoimmune response [41].
Alternatively, RA may not be the clinical consequence of the
misguided T-cell response to a selective set of autoantigens,
but it may represent a global defect in T-cell responsiveness
that is amenable to CTLA4-Ig treatment. There is indeed
evidence for this model; abnormalities that already occur in
the naïve T-cell compartment have been described [42].
The CD27-CD70 pathway
CD27 is a member of the TNF receptor family that shares
several features with CD28 [43]. It is also constitutively
expressed on naïve and central memory T cells, and it is
progressively lost with differentiation into effector cells. CD27
activity is induced by engagement of CD70, a molecule that is
found on activated T cells, B cells, and DCs. Expression of
CD70 is strictly controlled and occurs transiently after
activation. CD27 signaling can lower the threshold of the TCR
response to low-affinity antigens, it enhances proliferation and
survival, and it promotes differentiation [44,45]. Like many
other TNF-like receptors, CD27 signaling is TNF receptor-
associated factor (TRAF) dependent and primarily targets the
NF-κB and c-Jun amino-terminal kinase/p38 pathways.
The importance of the CD27-CD70 pathway to autoimmunity
is reflected in several murine models [46-48]. In the
physiological setting, CD27 stimulation is strictly controlled by
CD70 expression. Constitutive expression of CD70 under the
control of the CD19 promoter in transgenic mice leads to a
persistent stimulation of CD27. These mice exhibit a rapid
differentiation of CD4+ and CD8+ cells into effector cells,
presumably due to the recognition of autoantigens. T-cell
responses to exogenous antigen are initially increased.
However, mice eventually develop a progressive depletion of
the naïve T-cell pool and immune deficiency. In this context, it is
of particular interest that patients with systemic lupus
erythematosus (SLE) have a selective demethylation of the
CD70 promoter that leads to aberrant CD70 expression [49].
Also, in T cells from patients with RA, the regulation of CD70
expression is altered. Upon activation, CD4+ effector T cells
from patients with RA express CD70 for a prolonged period of
time, providing signals to CD27+ naïve T cells and facilitating
their activation and proliferation [50]. In analogy to the mouse
model, the over-expression of CD70 has the potential to recruit
and activate low-affinity T cells and to amplify T-cell responses.
Whether blocking of the CD27-CD70 pathway is efficacious in
RA or SLE is not known, but this intervention has been shown
to be beneficial in several animal models of autoimmunity,
including the autoimmune encephalomyelitis model [47].
The CD40-CD154 pathway
CD40 and its ligand, CD40L or CD154, were first identified
as instrumental in T-cell-dependent B-cell activation [51].
Antibody-mediated triggering of CD40 on B cells, in conjunc-
tion with B-cell receptor stimulation, induces B-cell prolifera-
tion and is essential for germinal center formation and isotype
switching. CD40 is constitutively expressed on B cells; its
ligand CD154 is induced on CD4+ T cells upon activation.
Expression of CD154 on CD8+ T cells is infrequent, but it
appears to be of importance in germinal center formation in
the synovial tissue [52]. The bearing of the CD40-CD154
receptor-ligand interaction for T-cell activation was
subsequently recognized; inhibition of this pathway greatly
reduced the activation of naïve T cells to antigen presented
by DCs, leading to the definition of CD154 as a co-
stimulatory molecule. More appropriately, the pathway is now
recognized as a mechanism to activate APCs and to enhance
their potential to activate T cells. CD154-mediated CD40
stimulation provides an important feedback mechanism for
the initial co-stimulatory pathway of CD28-CD80/CD86.
Initial suboptimal stimulation of CD4+ T cells induces CD154
to engage CD40 on DCs, which then upregulates the
expression of CD80 and CD86, facilitating further co-
stimulation through CD28. CD40-activated DCs can
stimulate CD8+ T cells without further T-cell help [53,54].
Therapeutic targeting of this pathway had beneficial effects in
rodent autoimmune and transplant models [9]. Anti-CD154
antibodies were highly efficacious in preventing acute
allograft rejections in nonhuman primates, but the effect was
less prominent in recall responses; this is consistent with the
model in which the CD154-CD40 pathway, interlinked with
CD80/86-CD28 co-stimulation, is of central importance in
primary T-cell responses. Treatment studies in human SLE,
however, identified the unexpected side effect of frequent
thromboembolic events [55]. It is now clear that platelets
secrete a soluble form of CD154, which is important in
thrombus formation and stability [56]. One but not the only
action of soluble CD154 is its binding of CD40 on
endothelial cells and promotion of their activation [57].
Studies employing direct targeting of CD40 rather than
CD154 may in part circumvent the thromboembolic side
effects, but they may be not without side effects, given the
widespread distribution of CD40.
Co-stimulatory signals provided by
activation-induced receptors
A set of co-stimulatory molecules is not constitutively
expressed on T cells, but is rapidly induced upon activation
and provides a second wave of co-stimulation (Figure 2)
[20,43]. Their major function is to sustain and to amplify the
T-cell response, but they are also involved in T-cell
differentiation and memory T-cell development. They have
been proven to be important in autoimmune diseases in
animal models, but their role in human disease is less well
defined. Classical examples are CD30, 4-1BB, and Ox40 of
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the immunoglobulin family.
ICOS is a CD28 homolog that is upregulated on naïve T cells
after activation and on memory and effector T cells [58,59].
Similar to CD28, its cytoplasmic domain has a sequence
motif that facilitates the binding of the p85 subunit of PI3-K
[60]. Its potency to activate the PI3-K/AKT signaling pathway
is greater than that of CD28; however, ICOS is also more
selective in its activation mechanisms and, in contrast to
CD28, it is unable to influence the c-Jun amino-terminal
kinase pathway or promote the production of interleukin-2.
Ligands for ICOS are constitutively expressed on APCs and,
in contrast to CD80 and CD86, do not underlie the control of
CD40 or signals involving the NF-κB pathway such as Toll-
like receptors. mRNAs for ICOS ligands are also found in a
variety of nonhematopoietic cells such as endothelial and
epithelial cells and fibroblasts. In vitro, ICOS stimulation
augments the production of various T-helper-1 and T-helper-2
cytokines, but does not contribute to clonal expansion.
Experiments in transgenic and knockout animals, as well as in
disease models, have generated a complex picture of its in
vivo function. ICOS co-stimulation appears to be of particular
importance for T-cell effector activity and for T-cell-dependent
B-cell responses [61]. In most autoimmune disease models,
ICOS blockade suppresses disease activity [62,63], but it
can also aggravate disease when it is given during the
induction rather than the effector stage [64].
Ox40 (CD134), 4-1BB (CD137), and CD30 have similar
functions in primary and secondary immune responses [43].
Their ligands are expressed on APCs, including B cells, but
they may also be present on nonhematopoietic cells, such as
endothelial cells. Ox40 is primarily inducible on CD4+ T cells,
whereas 4-1BB expression is observed preferentially in CD8+
cells, but this subset specificity is not absolute. Both mole-
cules are transiently expressed, and support the expansion of
T cells and differentiation into effector-cell populations. Ox40-
Ox40 ligand interaction has been shown to provide an
important co-stimulatory signal in murine models of auto-
immune encephalomyelitis, collagen-induced arthritis, and
autoimmune colitis [65-69]. Antibody-mediated inhibition
attenuated disease. In contrast, the role of 4-1BB in
autoimmune disease appears to be more complex. Treatment
with anti-4-1BB antibodies can have inhibitory as well as
stimulatory effects, depending on the disease [70]. A
possible explanation is that 4-1BB may be involved in the
activation and differentiation of a regulatory cell population
[71]. Expansion of CD8+ effector cells seen with agonistic
4-1BB-specific antibodies may have a regulatory impact on
immune responses; also, cell populations other than T cells
express 4-1BB and are influenced by agonistic antibodies.
CD30, in many respects, behaves similarly to Ox40 and
enhances proliferation and cytokine production induced by
TCR stimulation. CD30 co-stimulation has primarily been
explored in the NOD (nonobese diabetic) model of diabetes
because it maps to the diabetes susceptibility locus idd9.2
and revealed several sequence differences in NOD mice
compared with B10 mice [72].
In summary, a set of molecules is readily induced in T cells
upon TCR signaling and provides a second wave of co-
stimulation. Recognition of the ligands, mostly expressed on
APCs, sustains the immune response and amplifies the clonal
expansion or effector function. These co-stimulatory signals
are equally relevant for the priming of naïve as well as the
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Figure 2
Activation-induced co-stimulatory receptors and their ligands. Upon activation, T cells express a number of receptors that have co-stimulatory ability
and are important for sustained activation, proliferation, and differentiation. Their ligands again are expressed on antigen-presenting cells. ICOS,
inducible co-stimulator; MHC, major histocompatibility complex; TCR, T-cell receptor.recall of memory T cells. The functional consequences of
immune intervention targeting these receptor-ligand inter-
actions can be complex, depending on the timing, the stage
of the immune response, and the microenvironment; the
results can be difficult to predict.
Regulatory control of T effector cells
For effector subpopulations, the context of the environment
changes; in particular, CD8+ cells are no longer focused on
APCs but on parenchymal cells. It is therefore not surprising
that effector cells lose the expression of important co-
stimulatory receptors that function in the initiation of the
immune response, such as CD27 and CD28. Effector cell
populations continue to be responsive to 4-1BB triggering;
this receptor-ligand interaction may to some extent substitute
for the loss of signals derived by CD27 and CD28. In
addition, they gain the expression of regulatory molecules
(Figure 3), frequently borrowed from the repertoire of natural
killer (NK) cell receptors; these molecules include the killer
immunoglobulin-like receptor (KIR) and the immunoglobulin-
like transcript families, as well as natural-killer group 2,
member D (NKG2D) [73,74]. One characteristic feature of
these families is the inclusion of negative and positive
regulatory receptors that are co-expressed on individual cells;
the balance between positive and negative signals deter-
mines the outcome. How and when T cells gain the
expression of these molecules is unclear. Some of these
molecules are expressed on a large percentage of effector
cell populations; others are only present on small subsets. In
general, the expression of all of these regulatory receptors
favors CD8+ T cells, but they can also be found on CD4+
T cells [75]. One reason for this distribution pattern may be
that the frequency of CD8+ effector subpopulations is higher
than that of CD4+ T cells, in particular with increasing age.
Negative regulatory receptors have ITIM (immunoreceptor
tyrosine-based inhibitory motif) motifs in their cytoplasmic
domain that recruit Src homology 2 (SH2)-containing tyrosine
phosphatases (SHP) and exert inhibitory function when co-
engaged with the TCR [10]. In contrast to NK cells, these
inhibitory signals do not appear to be absolute, but rather
modify the functional response pattern of T cells [76]. Many
of these co-inhibitory receptors recognize common deter-
minants on MHC class I molecules.
The ligands for stimulatory KIR receptors are less well
defined, but may represent complexes of MHC class I mole-
cules and peptides. These stimulatory receptors are usually
expressed in the minority on individual cells, but they can
dominate selected effector cells in autoimmune diseases. The
function of the stimulatory receptors is entirely dependent on
adapter molecules that endow them with co-stimulatory or
stimulatory function [77]. An adapter molecule conferring full
stimulatory function is DAP12, which expresses an ITAM
motif [78]. In the presence of DAP12, T cells expressing
stimulatory KIR can be fully triggered just by the stimulation of
the activating KIR receptors in the absence of antigenic
stimulation [79]. In contrast, stimulatory KIR receptors
provide co-stimulatory signals in T cells that lack the
Arthritis Research & Therapy    Vol 10 Suppl 1 Goronzy and Weyand
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Figure 3
Co-stimulatory receptor-ligand pairs in the synovium. Effector T-cell populations frequently lose the expression of CD27 and CD28 and gain the
expression of regulatory receptors that bind to ligands in the synovium. In general, these receptors as well as their ligands are constitutively
expressed independent of cell activation. CD47 is expressed on all T cells irrespective of their differentiation status and receives a co-stimulatory
signal from a trimolecular complex formation including CD36 on synoviocytes or endothelial cells and thrombospondin produced in the synovial
tissue. KIR, killer immunoglobulin-like receptor; MHC, major histocompatibility complex; TCR, T-cell receptor.expression of DAP12 [80]. It is possible that in these T cells
DAP10 plays a role as an adapter molecule. DAP10 has a
PI3-K binding domain that resembles CD28 or ICOS and
initiates activation of the PI3-K pathway. Preferential
expression of co-stimulatory rather than co-inhibitory
receptors appears to contribute to unopposed effector cell
activity in chronic inflammatory diseases [81]. Stimulatory KIR
polymorphisms have been found to be associated with
psoriasis and extra-articular manifestations of RA [82].
Co-stimulatory ligands in the synovial tissue
It is the premise of co-stimulation to set the recognition of
antigen into the context of the immediate environment. For
naïve and central memory T cells, co-stimulatory signals are
provided by ligands expressed on DCs and other APCs,
which are plentiful in the inflamed synovium. Effector T cells
frequently receive regulatory signals from nonpolymorphic
determinants on MHC class I molecules that are expressed
on all somatic cells. In addition, synovial fibroblasts express
ligands that regulate T-cell responses specifically in the
synovial environment.
CD47 is a cell membrane protein of the immunoglobulin
superfamily with wide tissue distribution that has been impli-
cated in both integrin-dependent and integrin-independent
signaling cascades. It is expressed on all subsets of T cells,
including effector cell populations that have lost the classical
co-stimulatory molecules CD28 and CD27. Engagement in T
cells leads to F-actin polymerization, PKCθ recruitment, phos-
pholipase-γ activation, and calcium influx, amplifying TCR
stimulation and enhancing proliferation as well as cytokine
production [83]. In addition to the classical SIRP (signal
regulatory protein) ligands, CD47 binds to thrombospondin,
which is highly expressed in the synovial environment, in par-
ticular in diffuse synovitis that is poorly vascularized [84]. CD47
and thrombospondin can form a trimolecular complex with
CD36 expressed on synovial fibroblasts. This complex formation
is efficient in triggering CD47 activity in T cells [85,86].
NKG2D is a cell surface molecule that can fully activate NK
cells, but it has co-stimulatory function if found on T cells. Its
ligands include seven members of the MIC and the
ULBP/RAE families, which are induced as a stress response
in epithelial cells [87]. Several of these members are also
found to be expressed in synovial fibroblasts in RA [88,89].
NKG2D is constitutively expressed on human CD8+ T cells
and a subset of CD4+ effector cells, which is in contrast to
the rodent system, where its expression is activation depen-
dent. NKG2D signals through DAP10, activating the PI3-K
pathway [90]. The synovial microenvironment is therefore
poised to provide co-stimulatory signals to NKG2D-express-
ing CD4+ and CD8+ T cells.
Similar to NKG2D, the fractalkine receptor CX3CR1 (CX3C
chemokine receptor 1) is found on CD28- CD4+ T cells and
on the CD8+ effector T-cell population. CX3CR1 is a
G-protein-coupled receptor that provides a co-stimulatory
signal to complement TCR stimulation. Engagement of this
receptor enhances production of effector cytokines such as
TNF-α and interferon-γ [91]. Its ligand fractalkine is produced
by synovial fibroblasts and exists in a soluble and a cell-
bound form. Cell-bound fractalkine provides a co-stimulatory
signal to T cells. The increased production of TNF-α by the
effector T-cell population stimulates the synovial fibroblast to
produce soluble fractalkine, which is a growth factor for
fibroblast proliferation [92].
Conclusion
The concept of co-stimulation, initially originating from the
two-signal hypothesis, has developed into the broader notion
Available online http://arthritis-research.com/supplements/10/S1/S3
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Key messages
￿ T-cell activation requires a combination of TCR-
mediated and co-stimulatory signals.
￿ Although antigen recognition is the determining
factor for TCR stimulation, co-stimulatory stimuli
provide information on the cellular context where
recognition occurs.
￿ Interfering with co-stimulatory pathways has the
promise to modulate immune responses without
knowledge of the antigen.
￿ Co-stimulatory signals modify TCR signaling. T-cell
responses to high-affinity antigens can occur in the
absence of co-stimulatory signals. Conversely, co-
stimulatory signals can overcome unresponsiveness
to low-affinity antigens.
￿ Many co-stimulatory receptor-ligand pairs have been
described. Their roles depend on the differentiation
state of the T cell and the environment in which the
T-cell response occurs (Figures 1 to 3).
￿ The CD28-CD80/CD86 pathway is the classical co-
stimulatory pathway and has unique importance for
the initiation of naïve CD4+ T-cell responses that are
triggered by antigen presented by DCs (Figure 1).
￿ Activation-induced co-stimulatory molecules such as
Ox40, 4-1BB, and ICOS function to sustain and to
amplify the T-cell response and to regulate T-cell
differentiation into memory and effector cells (Figure 2).
￿ Co-stimulatory as well as co-inhibitory receptors on
effector T cells regulate the T-cell response in the
synovium by virtue of their ligands, which are
expressed on synoviocytes and parenchymal cells
(Figure 3).that T-cell responses are context dependent and are
influenced by signals from their environment through a variety
of receptor-ligand interactions. These signals amplify and
modify the original TCR signal received by antigenic
stimulation in a resting naïve or memory T cell, regulate T-cell
expansion and differentiation in recently activated T cells, or
control effector functions in a particular somatic environment.
Co-stimulation blockade attenuates or modifies T-cell
responses and therefore represents a powerful treatment tool
in autoimmune diseases. By its very nature, co-stimulation is
not antigen specific and therefore will not be specific for
autoimmune T-cell responses, but it also inhibits or modifies
responses to infectious or tumorigenic antigens. However,
immune responses in the various autoimmune diseases and
in normal responses may differ in their context dependency.
Co-stimulation blockade will be unlikely to restore tolerance
as originally envisioned, but selective pathway blockade or
defined temporal administration may have the potential to be
applied as a targeted intervention in an autoimmune disease.
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